ClinicalTrials.gg
Active, not recruitingNCT03755791COSMIC-312Updated Dec 11, 2025Results posted

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

A Phase 3 interventional study of Cabozantinib and Cabozantinib in Hepatocellular Carcinoma, sponsored by Exelixis. Active, not recruiting at 245 sites in 34 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2018, registered Nov 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
837
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing cabozantinib in Carcinoma, Hepatocellular — 7 open to participants now, 11 under way, 2 of them phase 3. cabozantinib · Carcinoma, Hepatocellular.

Enrollment
3rd of 27
837 · median 35
Started
2018
with 3 others
Phase 3
3 of 27
1 open now
Primary completion
2021-11
later than 1 of 10 live
Registered
9th of 27
by date
Lead sponsor
5 of 27
Exelixis

Among the 27 studies testing cabozantinib in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is one of 4 that started in 2018, is one of 3 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 9th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 27 studies testing cabozantinib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing cabozantinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which participants receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.

Read the detailed description

This is a multicenter, randomized, open-label, controlled Phase 3 trial of cabozantinib in combination with atezolizumab versus sorafenib in adults with advanced HCC who have not received previous systemic anticancer therapy in the advanced HCC setting. The primary objective of this study is to evaluate the effect of cabozantinib in combination with atezolizumab on the duration of progression-free survival (PFS) and duration of overall survival (OS) versus sorafenib. The secondary objective is to evaluate the activity of single-agent cabozantinib compared with sorafenib in this patient population.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • liver
  • cancer
  • hepatocellular
  • carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Histological or cytological diagnosis of HCC or clinical diagnosis of HCC in cirrhotic patients by Computed Tomography (CT) or Computed Tomography (MRI) per the American Association for the Study of Liver Diseases (AASLD) 2018 or European Association for the Study of the Liver (EASL) 2018 guidelines.
  • The participant has disease that is not amenable to a curative treatment approach (eg, transplant, surgery, ablation therapy) or locoregional therapy (eg, TACE).
  • per (RECIST) 1.1 as determined by the Investigator.
  • Barcelona Clinic Liver Cancer (BCLC) stage Category B or C.
  • Score of A.
  • (ECOG) performance status of 0 or 1.

Key Exclusion Criteria:

  • Known fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma.
  • Prior systemic anticancer therapy for advanced HCC including but not limited to chemotherapy, small molecule kinase inhibitors, and (ICIs). Participants who have received local intratumoral or arterial chemotherapy are eligible; local anticancer therapy within ≥ 28 days before randomization
  • Radiation therapy for bone within 2 weeks, any other radiation therapy within 8 weeks prior to randomization.
  • Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 8 weeks prior to randomization.
  • Concomitant anticoagulation with oral anticoagulants

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
837 participants (actual)

Study arms

  • Experimental
    Experimental arm

    Participants with advanced HCC will receive cabozantinib 40 milligrams (mg) oral, once daily (qd) + atezolizumab 1200 mg infusion, once every 3 weeks (q3w)

    Drug: Cabozantinib · Drug: Atezolizumab

  • Active comparator
    Control arm

    Participants with advanced HCC will receive sorafenib 400 mg twice a day (bid)

    Drug: Sorafenib

  • Other
    Single-Agent Cabozantinib arm

    Participants with advanced HCC will receive cabozantinib 60 mg qd

    Drug: Cabozantinib

Interventions

  • Supplied as 20-mg tablets; administered orally daily at 40 mg

    Also known as: XL184, Cabometyx®

  • Supplied as 60-mg tablets; administered orally once daily at 60 mg

    Also known as: XL184, Cabometyx®

  • Supplied as 200-mg tablets; administered orally twice daily at 400 mg

    Also known as: Nexavar®

  • Supplied as 1200 mg/20 mL (60 mg/mL) in sing-dose vials; administered as an intravenous (IV) infusion q3w

    Also known as: Tecentriq®

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population

    PFS was defined as the time from randomization to the earlier of either the date of radiographic progression defined as a 20% increase in the sum of the longest diameters of target lesions, or the unequivocal appearance of new lesions, or progression of non-target disease per Blinded Independent Radiology Committee (BIRC) or the date of death due to any cause per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: From the date of first participant randomization up to 28 months

  2. Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population

    OS was defined as the time from randomization to death due to any cause.

    Time frame: From the date of first participant randomization up to 36 months

Secondary outcomes

  1. PFS for the Single-Agent Cabozantinib Arm Versus the Control Arm in the ITT Population

    PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause per RECIST version 1.1.

    Time frame: From the date of first participant randomization up to 28 months

07

Results

Posted Dec 11, 2025

Participant flow

Participant flow — Overall Study
MilestoneExperimental Arm: Cabozantinib + AtezolizumabSingle-Agent CabozantinibControl Arm: Sorafenib
Started432188217
Received at least 1 dose of study drug429188207
Completed000
Not completed432188217
Withdrew: Did not receive any study treatment3010
Withdrew: Radiographic progression20492115
Withdrew: Adverse event1406051
Withdrew: Lack of efficacy1266
Withdrew: Withdrawal by subject262324
Withdrew: Sponsor decision,4157
Withdrew: Lost to follow-up102
Withdrew: Protocol violation002
Withdrew: Other than specified520

Outcome measures

PrimaryProgression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population

PFS was defined as the time from randomization to the earlier of either the date of radiographic progression defined as a 20% increase in the sum of the longest diameters of target lesions, or the unequivocal appearance of new lesions, or progression of non-target disease per Blinded Independent Radiology Committee (BIRC) or the date of death due to any cause per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Time frame:
From the date of first participant randomization up to 28 months
Reported as:
Median · months
Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population
monthsExperimental Arm: Cabozantinib + AtezolizumabControl Arm: Sorafenib
Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population6.80 (5.55 to 8.34)4.21 (2.79 to 7.03)
Statistical analysis
  • Experimental Arm: Cabozantinib + Atezolizumab vs Control Arm: Sorafenib · Log Rank · p = 0.0012 · Hazard ratio (hr): 0.63 · 99% CI 0.44 to 0.91
PrimaryOverall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population

OS was defined as the time from randomization to death due to any cause.

Time frame:
From the date of first participant randomization up to 36 months
Reported as:
Mean · months
Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population
monthsExperimental Arm: Cabozantinib + AtezolizumabControl Arm: Sorafenib
Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population16.46 (14.46 to 18.56)15.51 (12.19 to 19.98)
Statistical analysis
  • Experimental Arm: Cabozantinib + Atezolizumab vs Control Arm: Sorafenib · Log Rank · p = 0.9056 · Hazard ratio (hr): 0.99 · 96% CI 0.78 to 1.24
SecondaryPFS for the Single-Agent Cabozantinib Arm Versus the Control Arm in the ITT Population

PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause per RECIST version 1.1.

Time frame:
From the date of first participant randomization up to 28 months
Reported as:
Median · months
PFS for the Single-Agent Cabozantinib Arm Versus the Control Arm in the ITT Population
monthsSingle-Agent CabozantinibControl Arm: Sorafenib
PFS for the Single-Agent Cabozantinib Arm Versus the Control Arm in the ITT Population5.82 (5.42 to 8.18)4.27 (2.86 to 6.11)

Adverse events

Collected over Up to 39 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm: Cabozantinib + Atezolizumab307/429 (71.6%)226/429 (52.7%)414/429 (96.5%)
Single-Agent Cabozantinib135/188 (71.8%)88/188 (46.8%)182/188 (96.8%)
Control Arm: Sorafenib141/207 (68.1%)85/207 (41.1%)202/207 (97.6%)
Most frequent serious events
Showing 10 of 257
Most frequent serious events
EventExperimental Arm: Cabozantinib + AtezolizumabSingle-Agent CabozantinibControl Arm: Sorafenib
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)38/42926/18818/207
Hepatic encephalopathyNervous system disorders12/4297/1881/207
AscitesGastrointestinal disorders15/4293/1883/207
COVID-19Infections and infestations12/4293/1882/207
PyrexiaGeneral disorders11/4291/1881/207
SepsisInfections and infestations11/4294/1882/207
Abdominal painGastrointestinal disorders8/4294/1884/207
DiarrhoeaGastrointestinal disorders9/4294/1880/207
Hepatic failureHepatobiliary disorders8/4294/1882/207
PneumoniaInfections and infestations7/4294/1883/207
Most frequent other events
Showing 10 of 60
Most frequent other events
EventExperimental Arm: Cabozantinib + AtezolizumabSingle-Agent CabozantinibControl Arm: Sorafenib
DiarrhoeaGastrointestinal disorders215/429102/18898/207
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders185/42982/18892/207
Decreased appetiteMetabolism and nutrition disorders128/42981/18843/207
Aspartate aminotransferase increasedInvestigations138/42961/18830/207
FatigueGeneral disorders113/42960/18836/207
Alanine aminotransferase increasedInvestigations134/42956/18824/207
HypertensionVascular disorders106/42956/18839/207
Weight decreasedInvestigations82/42948/18833/207
HypothyroidismEndocrine disorders93/42936/1889/207
NauseaGastrointestinal disorders70/42940/18830/207

Baseline characteristics

The Intent-to-Treat (ITT) population consisted of all participants who were randomized to any of the three study treatment arms, regardless of whether they received any study treatment.

Age, Categorical
Age, Categorical(Participants)Experimental Arm: Cabozantinib + AtezolizumabSingle-Agent CabozantinibControl Arm: SorafenibTotal
<=18 years0000
Between 18 and 65 years23497112443
>=65 years19891105394
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Arm: Cabozantinib + AtezolizumabSingle-Agent CabozantinibControl Arm: SorafenibTotal
Female723031133
Male360158186704
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Experimental Arm: Cabozantinib + AtezolizumabSingle-Agent CabozantinibControl Arm: SorafenibTotal
Hispanic or Latino42211578
Not Hispanic or Latino352158183693
Not Reported3891966
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Experimental Arm: Cabozantinib + AtezolizumabSingle-Agent CabozantinibControl Arm: SorafenibTotal
Asian1276472263
Black/African American85114
White21795111423
Other than specified802433137
08

Study locations

245 sites
  • Exelixis Clinical Site #208
    Phoenix, Arizona 85004, United States
  • Exelixis Clinical Site #159
    Tucson, Arizona 85719, United States
  • Exelixis Clinical Site #44
    La Jolla, California 92037, United States
  • Exelixis Clinical Site #112
    Los Angeles, California 90033, United States
  • Exelixis Clinical Site #200
    Orange, California 92868-3201, United States
  • Exelixis Clinical Site #2
    Rialto, California 92377, United States
  • Exelixis Clinical Site #207
    San Diego, California 92093, United States
  • Exelixis Clinical Site #109
    San Francisco, California 94115, United States
  • Exelixis Clinical Site #54
    San Francisco, California 94158, United States
  • Exelixis Clinical Site #58
    Washington D.C., District of Columbia 20007, United States
  • Exelixis Clinical Site #191
    Miami, Florida 33125, United States
  • Exelixis Clinical Site #4
    Atlanta, Georgia 30318, United States
  • Exelixis Clinical Site #195
    Chicago, Illinois 60612, United States
  • Exelixis Clinical Site #120
    Chicago, Illinois 60637, United States
  • Exelixis Clinical Site #6
    Baltimore, Maryland 21202, United States
  • Exelixis Clinical Site #7
    Burlington, Massachusetts 01805, United States
  • Exelixis Clinical Site #11
    Kansas City, Missouri 64128, United States
  • Exelixis Clinical Site #5
    Kansas City, Missouri 64131, United States
  • Exelixis Clinical Site #8
    St Louis, Missouri 63110, United States
  • Exelixis Clinical Site #1
    Las Vegas, Nevada 89169, United States
  • Exelixis Clinical Site #14
    New Brunswick, New Jersey 08903, United States
  • Exelixis Clinical Site #76
    Albuquerque, New Mexico 87131, United States
  • Exelixis Clinical Site #12
    Chapel Hill, North Carolina 27599-7600, United States
  • Exelixis Clinical Site #39
    Toledo, Ohio 43614, United States
  • Exelixis Clinical Site #176
    Portland, Oregon 97213, United States
  • Exelixis Clinical Site #88
    Philadelphia, Pennsylvania 19107, United States
  • Exelixis Clinical Site #144
    Charleston, South Carolina 29425, United States
  • Exelixis Clinical Site #199
    Dallas, Texas 75246, United States
  • Exelixis Clinical Site #154
    Houston, Texas 77030, United States
  • Exelixis Clinical Site #19
    Temple, Texas 76508, United States
  • Exelixis Clinical Site #13
    Seattle, Washington 98101, United States
  • Exelixis Clinical Site #46
    Seattle, Washington 98109, United States
  • Exelixis Clinical Site #3
    Spokane, Washington 99208, United States
  • Exelixis Clinical Site #217
    City of Buenos Aires, Buenos Aires C1118AAT, Argentina
  • Exelixis Clinical Site #213
    City of Buenos Aires, Buenos Aires C1199ABB, Argentina
  • Exelixis Clinical Site #216
    City of Buenos Aires, Buenos Aires C1264AAA, Argentina
  • Exelixis Clinical Site #219
    Pilar, Buenos Aires B1629ODT, Argentina
  • Exelixis Clinical Site #220
    Rosario, Santa Fe Province 2000, Argentina
  • Exelixis Clinical Site #201
    Rosario, Santa Fe Province S2000CVB, Argentina
  • Exelixis Clinical Site #78
    Camperdown, New South Wales 2050, Australia
  • Exelixis Clinical Site #165
    Darlinghurst, New South Wales 2010, Australia
  • Exelixis Clinical Site #171
    Kingswood, New South Wales 2747, Australia
  • Exelixis Clinical Site #126
    Kogarah, New South Wales 2217, Australia
  • Exelixis Clinical Site #155
    Westmead, New South Wales 2145, Australia
  • Exelixis Clinical Site #142
    Greenslopes, Queensland 4120, Australia
  • Exelixis Clinical Site #17
    Kurralta Park, South Australia, Australia
  • Exelixis Clinical Site #107
    Box Hill, Victoria 3128, Australia
  • Exelixis Clinical Site #166
    Heidelberg, Victoria 3084, Australia
  • Exelixis Clinical Site #72
    Parkville, Victoria 3050, Australia
  • Exelixis Clinical Site #190
    Nedlands, Western Australia 6009, Australia
  • Exelixis Clinical Site #150
    Klagenfurt, Carinthia 9020, Austria
  • Exelixis Clinical Site #137
    Sankt Pölten, Lower Austria 3100, Austria
  • Exelixis Clinical Site #198
    Graz, Styria 8036, Austria
  • Exelixis Clinical Site #64
    Linz, Upper Austria 4010, Austria
  • Exelixis Clinical Site #174
    Vienna, 1090, Austria
  • Exelixis Clinical Site #50
    Brussels, California 1070, Belgium
  • Exelixis Clinical Site #65
    Brussels, 1200, Belgium
  • Exelixis Clinical Site #169
    Edegem, 2650, Belgium
  • Exelixis Clinical Site #148
    Ghent, 9000, Belgium
  • Exelixis Clinical Site #57
    Haine-Saint-Paul, 7100, Belgium
  • Exelixis Clinical Site #188
    Leuven, 3000, Belgium
  • Exelixis Clinical Site #102
    Liège, 4000, Belgium
  • Exelixis Clinical Site #184
    Salvador, Estado de Bahia 40110-060, Brazil
  • Exelixis Clinical Site #89
    Belo Horizonte, Minas Gerais 30110-022, Brazil
  • Exelixis Clinical Site #98
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Exelixis Clinical Site #113
    Curitiba, Paraná 81520-060, Brazil
  • Exelixis Clinical Site #203
    Porto Alegre, Rio Grande do Sul 90050-170, Brazil
  • Exelixis Clinical Site #175
    Barretos, São Paulo 14784-400, Brazil
  • Exelixis Clinical Site #121
    Jaú, São Paulo 17210-120, Brazil
  • Exelixis Clinical Site #186
    São Paulo, São Paulo 01246-900, Brazil
  • Exelixis Clinical Site #156
    São Paulo, São Paulo 01321-001, Brazil
  • Exelixis Clinical Site #187
    São Paulo, São Paulo 01509-010, Brazil
  • Exelixis Clinical Site #181
    São Paulo, São Paulo 04538-132, Brazil
  • Exelixis Clinical Site #91
    São Paulo, 04543-000, Brazil
  • Exelixis Clinical Site #71
    Calgary, Alberta T2N 4N2, Canada
  • Exelixis Clinical Site #205
    Edmonton, Alberta T6G 2B7, Canada
  • Exelixis Clinical Site #34
    Winnipeg, Manitoba R3E 0V9, Canada
  • Exelixis Clinical Site #222
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Exelixis Clinical Site #194
    Hamilton, Ontario L8V 5C2, Canada
  • Exelixis Clinical Site #212
    Ottawa, Ontario K1H 8L6, Canada
  • Exelixis Clinical Site #85
    Montreal, Quebec H3T 1E2, Canada
  • Exelixis Clinical Site #233
    Hefei, Anhui 230036, China
  • Exelixis Clinical Site #228
    Fuzhou, Fujian 350014, China
  • Exelixis Clinical Site #225
    Xiamen, Fujian 361004, China
  • Exelixis Clinical Site #242
    Guangzhou, Guangdong 510280, China
  • Exelixis Clinical Site #227
    Harbin, Heilongjiang 150081, China
  • Exelixis Clinical Site #230
    Zhengzhou, Henan 450008, China
  • Exelixis Clinical Site #231
    Changsha, Hunan 410008, China
  • Exelixis Clinical Site #224
    Changsha, Hunan 410013, China
  • Exelixis Site #241
    Changsha, Hunan 410013, China
  • Exelixis Clinical Site #185
    Nanjing, Jiangsu 210002, China
  • Exelixis Clinical Site #221
    Nanchang, Jiangxi 330006, China
  • Exelixis Clinical Site #238
    Nanchang, Jiangxi 330006, China
  • Exelixis Clinical Site #234
    Jiangyin, Jiansu 214400, China
  • Exelixis Clinical Site #246
    Changchun, Jilin 130012, China
  • Exelixis Clinical Site #229
    Changchun, Jilin 130021, China
  • Exelixis Clinical Site #236
    Shenyang, Liaoning 110006, China
  • Exelixis Clinical Site #226
    Linyi, Shandong 276000, China
  • Exelixis Clinical Site #235
    Chengdu, Sichuan 610041, China
  • Exelixis Clinical Site #218
    Hangzhou, Zhejiang 310016, China

Showing the first 100 of 245 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13. PubMed 38364832 ↗
  • Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4. PubMed 35798016 ↗
  • Kelley RK, W Oliver J, Hazra S, Benzaghou F, Yau T, Cheng AL, Rimassa L. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncol. 2020 Jul;16(21):1525-1536. doi: 10.2217/fon-2020-0283. Epub 2020 Jun 3. PubMed 32491932 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Nov 2021, 41 months.

Results were first posted in Dec 2025, 4 years after primary completion. A results delay was requested in Mar 2022.

Of 52 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 41 months is below that.

Counting every sponsor, half of 138 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2018
First posted
Nov 28, 2018
StartActual
Jun 10, 2018
Primary completionActual
Nov 30, 2021
CompletionEst.
Jul 31, 2026
Results delay requested
Mar 8, 2022
Results first posted
Dec 11, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03755791
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Nov 28, 2018
Start date
Jun 10, 2018
Primary completion
Nov 30, 2021
Completion
Jul 31, 2026 (estimated)
Results posted
Dec 11, 2025
Last update
Dec 11, 2025

Study contacts

Medical Director
study director · Exelixis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabozantinib · Atezolizumab

Start the discussion